Ra Pharmaceuticals Inc (RARX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2014 | |
| Cash Flows From Operating Activities | |
| Net Income | -5,476 |
| Depreciation Amortization | 714 |
| Other Working Capital | -1,276 |
| Other Operating Activity | -1,513 |
| Operating Cash Flow | $-7,551 |
| Cash Flows From Investing Activities | |
| PPE Investments | -825 |
| Investing Cash Flow | $-825 |
| Cash Flows From Financing Activities | |
| Common Stock Issued | 13 |
| Other Financing Activity | 8,631 |
| Financing Cash Flow | $8,644 |
| Beginning Cash Position | 3,771 |
| End Cash Position | 4,039 |
| Net Cash Flow | $268 |
| Free Cash Flow | |
| Operating Cash Flow | -7,551 |
| Capital Expenditure | -834 |
| Free Cash Flow | -8,385 |